Literature DB >> 27473193

Pembrolizumab for relapsed anaplastic large cell lymphoma after allogeneic haematopoietic stem cell transplantation: efficacy and safety.

Thomas S Y Chan1, Pek-Lan Khong2, Yok-Lam Kwong3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27473193     DOI： 10.1007/s00277-016-2764-1

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  19 in total

1.  Dynamics of Lymphocyte Reconstitution After Hematopoietic Transplantation During Chronic Lymphocytic Choriomeningitis Virus Infection.

Authors:  Mitra Bhattacharyya; Pablo Penaloza-MacMaster
Journal:  AIDS Res Hum Retroviruses       Date:  2018-04-18       Impact factor: 2.205

Review 2.  Immune Checkpoint Blockade and Hematopoietic Stem Cell Transplant.

Authors:  Reid W Merryman; Philippe Armand
Journal:  Curr Hematol Malig Rep       Date:  2017-02       Impact factor: 3.952

Review 3.  Immune checkpoint inhibitors in challenging populations.

Authors:  Douglas B Johnson; Ryan J Sullivan; Alexander M Menzies
Journal:  Cancer       Date:  2017-02-27       Impact factor: 6.860

4.  PD-1 checkpoint blockade in patients with relapsed AML after allogeneic stem cell transplantation.

Authors:  J C Albring; S Inselmann; T Sauer; C Schliemann; B Altvater; S Kailayangiri; C Rössig; W Hartmann; J R Knorrenschild; K Sohlbach; C Groth; M Lohoff; A Neubauer; W E Berdel; A Burchert; M Stelljes
Journal:  Bone Marrow Transplant       Date:  2016-11-28       Impact factor: 5.483

Review 5.  Significant Risk of Graft-versus-Host Disease with Exposure to Checkpoint Inhibitors before and after Allogeneic Transplantation.

Authors:  Awais Ijaz; Ali Younas Khan; Saad Ullah Malik; Warda Faridi; Muhammad Asad Fraz; Muhammad Usman; Muhammad Junaid Tariq; Seren Durer; Ceren Durer; Atlantis Russ; Nadia Nunes Cavalcante Parr; Zeeshan Baig; Fnu Sagar; Zeeshan Ali; Ali McBride; Faiz Anwer
Journal:  Biol Blood Marrow Transplant       Date:  2018-09-06       Impact factor: 5.742

6.  PD-L1 expression is associated with ALK positivity and STAT3 activation, but not outcome in patients with systemic anaplastic large cell lymphoma.

Authors:  Jing Shen; Shaoying Li; L Jeffrey Medeiros; Pei Lin; Sa A Wang; Guilin Tang; C Cameron Yin; M James You; Joseph D Khoury; Swaminathan P Iyer; Roberto N Miranda; Jie Xu
Journal:  Mod Pathol       Date:  2019-08-05       Impact factor: 7.842

Review 7.  Recent advances in understanding and managing T-cell lymphoma.

Authors:  Jun Ho Yi; Seok Jin Kim; Won Seog Kim
Journal:  F1000Res       Date:  2017-12-12

Review 8.  The Role of Immune Checkpoints after Cellular Therapy.

Authors:  Friederike Schmitz; Dominik Wolf; Tobias A W Holderried
Journal:  Int J Mol Sci       Date:  2020-05-21       Impact factor: 5.923

Review 9.  Treatment Options for Paediatric Anaplastic Large Cell Lymphoma (ALCL): Current Standard and beyond.

Authors:  Nina Prokoph; Hugo Larose; Megan S Lim; G A Amos Burke; Suzanne D Turner
Journal:  Cancers (Basel)       Date:  2018-03-30       Impact factor: 6.639

10.  Blockade of programmed cell death protein 1 (PD-1) in Sézary syndrome reduces Th2 phenotype of non-tumoral T lymphocytes but may enhance tumor proliferation.

Authors:  Ieva Saulite; Desislava Ignatova; Yun-Tsan Chang; Christina Fassnacht; Florentia Dimitriou; Eleni Varypataki; Florian Anzengruber; Mirjam Nägeli; Antonio Cozzio; Reinhard Dummer; Julia Scarisbrick; Steve Pascolo; Wolfram Hoetzenecker; Malgorzata Bobrowicz; Emmanuella Guenova
Journal:  Oncoimmunology       Date:  2020-03-18       Impact factor: 8.110
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.